5th Annual Immunology Bootcamp in Conjunction With AWIR: Optimizing Outcomes for Patients With Immune-Mediated Inflammatory Diseases

2.00 CME
120 MINS
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Faculty Photo


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by educational grants from AbbVie Inc.; Bristol-Myers Squibb; and Janssen Scientific Affairs, LLC.

Activity Description

Immune-mediated inflammatory disease (IMID) is a group of clinically heterogeneous autoimmune disorders that includes rheumatoid arthritis, psoriasis, psoriatic arthritis, giant cell arteritis, and axial spondyloarthritis. Recognizing the underlying immunopathologic mechanisms of these disorders is essential for understanding how new and emerging biologic and small molecule therapies exert their effects, so they can be optimally incorporated into current management strategies. In this CME/ABIM MOC activity, held during the Association of Women in Rheumatology National Conference, experts in the field will examine common signaling pathways underlying IMID, evaluate the latest clinical evidence for available and emerging steroid-sparing therapies targeting these signaling pathways, and discuss the latest recommendations to inform individualized treatment approaches.

Target Audience

The intended audience for this activity is rheumatologists, internists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Review the latest understanding regarding key signaling molecules involved in IMID, including those targeted by new and emerging biologic or small molecule therapies.
  • Select treatment for patients with AxSpA, PsA, or PsO using the latest recommendations and clinical evidence.
  • Apply the latest evidence to the management of patients with inflammatory skin disease.

Activity Chair

Grace C. Wright, MD, PhD, FACR
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY


Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Christopher T. Ritchlin, MD, MPH
Professor and Chief
Allergy, Immunology and Rheumatology Division
University of Rochester Medical Center
Rochester, NY 

Junko Takeshita, MD, PhD, MSCE
Assistant Professor
Department of Dermatology
Department of Biostatistics, Epidemiology and Informatics
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA 


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Successful completion of this CME activity enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in by proving their DOB (MM/DD) and their ABIM ID will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, September 30, 2021, to September 29, 2022.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 5 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Grace C. Wright, MD, PhD, FACR
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Lilly, Myriad Autoimmune, Novartis, Pfizer, Sanofi Genzyme, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Lilly, Myriad Autoimmune, Novartis, Sanofi Genzyme, UCB

Leonard H. Calabrese, DO
Consulting Fee: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Pfizer, Regeneron, Sanofi-Genzyme, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Christopher T. Ritchlin, MD, MPH
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Kaleido, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun, UCB
Contracted Research: AbbVie, UCB

Junko Takeshita, MD, PhD, MSCE
Consulting Fee: Janssen, Pfizer
Contracted Research (Paid to Institution): Pfizer

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose. 

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non—FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com